Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

0

Why Impax Laboratories Shares Slumped

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of generic-drug maker Impax Laboratories (Nasdaq: IPXL  ) are under the weather today, falling as much as 10%, following news that its chief financial officer is resigning.

So what: Impax announced before the bell this morning that Arthur Koch was resigning, although he will help with the transition. Impax also announced that Bryan Reasons, who is currently the vice president of finance, has been appointed as acting CFO while the company conducts its search for a permanent CFO.

Now what: Koch had served as CFO since 2005; it's never a good sign to see a high-ranking, long-tenured executive leave a company. However, it doesn't appear there are any red flags surrounding Koch's departure, so I wouldn't let today's news change your investment thesis on the company. Personally, I'd consider using today's move lower as a potential buying opportunity into Impax as its role in generics is only likely to expand.

Craving more input? Start by adding Impax Laboratories to your free and personalized watchlist so you can keep up on the latest news with the company.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 1929080, ~/Articles/ArticleHandler.aspx, 5/25/2013 11:03:12 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 15,303.10 8.60 0.06%
S&P 500 1,649.60 -0.91 -0.06%
NASD 3,459.14 -0.28 -0.01%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/24/2013 4:00 PM
IPXL $18.80 Up +0.20 +1.08%
Impax Laboratories… CAPS Rating: ***

Advertisement